Join

Compare · BTTX vs NVO

BTTX vs NVO

Side-by-side comparison of Better Therapeutics Inc. (BTTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BTTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $195.92B, about 2299.7x BTTX ($85.2M).
  • NVO has hit the wire 3 times in the past 4 weeks while BTTX has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 2 for BTTX).
MetricBTTXNVO
Company
Better Therapeutics Inc.
Novo Nordisk A/S
Price
$0.05+28.53%
$43.88-0.20%
Market cap
$85.2M
$195.92B
1M return
-
-6.80%
1Y return
-
-43.03%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
3
Recent ratings
2
25
BTTX

Better Therapeutics Inc.

Better Therapeutics, Inc. develops prescription digital therapeutics that delivers behavioral therapy, and creates feedback mechanisms using remotely monitored and patient-generated data. Its products include Nutritional Cognitive Behavioral Therapy (Nutritional CBT), behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It also manufactures therapeutic medicines, such as BT—001, BT—002, BT—003, BT—004, and BT—005 for cardiometabolic diseases. The company was incorporated in 2015 and is based in San Francisco, California.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest BTTX

Latest NVO